

Alan C Rapraeger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8003955/publications.pdf>

Version: 2024-02-01

22
papers

1,941
citations

394421

19
h-index

677142

22
g-index

24
all docs

24
docs citations

24
times ranked

1859
citing authors

#	ARTICLE	IF	CITATIONS
1	Syndecan-1 regulates $\alpha 3$ and $\alpha 5$ integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. <i>Journal of Experimental Medicine</i> , 2009, 206, 691-705.	8.5	249
2	The syndecan-1 ectodomain regulates $\alpha 3$ integrin activity in human mammary carcinoma cells. <i>Journal of Cell Biology</i> , 2004, 167, 171-181.	5.2	217
3	Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. <i>Blood</i> , 2010, 115, 2449-2457.	1.4	198
4	Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. <i>FEBS Journal</i> , 2017, 284, 42-55.	4.7	182
5	Syndecan-1-mediated cell spreading requires signaling by $\alpha 3$ integrins in human breast carcinoma cells. <i>Experimental Cell Research</i> , 2003, 286, 219-232.	2.6	136
6	Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation. <i>Journal of Cell Science</i> , 2010, 123, 3796-3807.	2.0	104
7	Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex <i>in situ</i> . <i>FASEB Journal</i> , 2000, 14, 137-144.	0.5	102
8	Syndecan-1 regulates $\alpha 5$ integrin activity in B82L fibroblasts. <i>Journal of Cell Science</i> , 2006, 119, 2445-2456.	2.0	97
9	Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R $\alpha 3$ integrin complex in tumorigenesis and angiogenesis. <i>FEBS Journal</i> , 2013, 280, 2207-2215.	4.7	96
10	Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between $\alpha 3$ integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesis. <i>FEBS Journal</i> , 2013, 280, 2194-2206.	4.7	70
11	Identification of an Adhesion Site within the Syndecan-4 Extracellular Protein Domain. <i>Journal of Biological Chemistry</i> , 1997, 272, 12901-12904.	3.4	62
12	Interaction of Syndecan and $\alpha 4$ Integrin Cytoplasmic Domains. <i>Journal of Biological Chemistry</i> , 2010, 285, 13569-13579.	3.4	62
13	Characterization of the High Affinity Cell-binding Domain in the Cell Surface Proteoglycan Syndecan-4. <i>Journal of Biological Chemistry</i> , 1998, 273, 28270-28276.	3.4	61
14	Tyrosine Phosphorylation of Syndecan-1 and -4 Cytoplasmic Domains in Adherent B82 Fibroblasts. <i>Journal of Biological Chemistry</i> , 1998, 273, 35291-35298.	3.4	59
15	Syndecan-1 and Syndecan-4 Capture Epidermal Growth Factor Receptor Family Members and the $\alpha 1$ Integrin Via Binding Sites in Their Ectodomains. <i>Journal of Biological Chemistry</i> , 2015, 290, 26103-26113.	3.4	58
16	Cytoplasmic Domain Interactions of Syndecan-1 and Syndecan-4 with $\alpha 4$ Integrin Mediate Human Epidermal Growth Factor Receptor (HER1 and HER2)-dependent Motility and Survival. <i>Journal of Biological Chemistry</i> , 2014, 289, 30318-30332.	3.4	56
17	Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by Synstatin/IGF1R Inhibits Tumor Growth. <i>Cancer Research</i> , 2016, 76, 4981-4993.	0.9	48
18	Transmembrane and Extracellular Domains of Syndecan-1 Have Distinct Functions in Regulating Lung Epithelial Migration and Adhesion. <i>Journal of Biological Chemistry</i> , 2012, 287, 34927-34935.	3.4	29

#	ARTICLE	IF	CITATIONS
19	The Specificity of EGF-Stimulated IQGAP1 Scaffold Towards the PI3K-Akt Pathway is Defined by the IQ3 motif. <i>Scientific Reports</i> , 2019, 9, 9126.	3.3	26
20	VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1. <i>Journal of Cell Science</i> , 2019, 132, .	2.0	13
21	Syndecans and Their Synstatins: Targeting an Organizer of Receptor Tyrosine Kinase Signaling at the Cell-Matrix Interface. <i>Frontiers in Oncology</i> , 2021, 11, 775349.	2.8	10
22	Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression. <i>Journal of Biological Chemistry</i> , 2022, 298, 102029.	3.4	4